Announcements
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
- Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
More ▼
Key statistics
On Tuesday, Fate Therapeutics Inc (F6T:DUS) closed at 4.73, -38.05% below its 52-week high of 7.63, set on Mar 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.10 |
---|---|
High | 4.73 |
Low | 4.10 |
Bid | 5.11 |
Offer | 5.15 |
Previous close | 4.02 |
Average volume | 3.13k |
---|---|
Shares outstanding | 113.83m |
Free float | 112.03m |
P/E (TTM) | -- |
Market cap | 519.07m USD |
EPS (TTM) | -1.92 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 18:31 BST.
More ▼